Tag: Cguard EPS

InspireMD presents positive 30-day follow-up results from C-GUARDIANS clinical trial

InspireMD recently presented 30-day results from the C-GUARDIANS US investigational device exemption (IDE) clinical trial evaluating its CGuard embolic prevention stent (EPS) system for...

SIBERIA trial: Positive one-month results for embolic prevention system

InspireMD has announced positive interim results from the SIBERIA trial, an investigator-initiated study of the CGuard embolic prevention system (EPS). The data were presented...
EPS

Regulatory and reimbursement approval of CGuard EPS in Australia

CGuard Embolic Prevention System (EPS) (InspireMD) has been granted regulatory approval by the Therapeutic Goods Administration (part of the Australian Government’s Department of Health)...

Expanded two-year follow-up results from the PARADIGM clinical study using CGuard...

Piotr Musiałek, from the Department of Cardiac and Vascular Diseases, John Paul II Hospital, Kraków, Poland, presented the expanded 24-month follow-up results from the...

InspireMD announces expansion of its distribution network for CGuard EPS

InspireMD has announced it has signed Diverse Devices as its exclusive distributor for Australia and New Zealand, and has signed Do Gia Production...